7% increase for Immutep share price – Clinical trials progress (ASX: IMM)

Small-cap biotech stocks Immutep Ltd [ASX:IMM] is on the rise today.

The IMM stock price is currently trading 7.92% higher at the time of writing. Soaring thanks to some positive news regarding the company’s ongoing clinical trials.

Let’s dig deeper into the details …

Final patient recruited

The big update of Immutep today is that it has recruited and dosed the last patient for its stage 2, part B study of its “efti” treatment. A variant of the broader immune control mechanism of the lymphocyte activation gene-3 (LAG-3).

The study in question examines the effects of efiT in patients with non-small cell lung cancer (NSCLC). With 154 patients now recruited and involved in the trial in three parts – A, B and C – for the study, out of a potential total of 183.

So, suffice to say that Immutep is progressing well. Secure many patients in order to obtain as much data as possible from this trial. Data that will determine how effective efti is.

As the company explains:

TACTI-002 is an emerging study in terms of PD-L1 status, a well-known predictor of response to pembrolizumab as monotherapy, particularly in NSCLC and HNSCC [Head and Neck Squamous Cell Carcinoma].

PD-L1 expression is generally reported in three groups for NSCLC: ‘

In other words, if efti can produce a meaningful result (as Immutep expects) then it could be a huge breakthrough. A new and unprecedented solution to treat these aggressive cancers.

PS: We unveil four little-known and essential small caps… Download your free report now.

What’s next for the Immutep share price?

Beyond today’s news, Immutep’s larger objective is obviously to finalize this phase II trial. The result of which will indicate not only the effectiveness of their treatment, but also the possibility of moving to a phase III trial.

After all, for any drug development company, this is the ultimate goal. The final end point before moving on to the marketing stage.

So, investors will want to keep a close eye on future updates. Because when the results are in, this stock is likely to soar or collapse. This is the nature of many biotech small caps.

If biotech isn’t your interest, or you’re looking for equally promising small caps, then we’ve got seven stocks you need to know right now. A collection of some of the best opportunities ASX has to offer right now, and you can read all about them here.

Because Immutep is certainly not the only small cap to impose itself on the market at the moment …


Ryan Clarkson-Ledward,
For Morning money

PS: Our Money Morning post is a great place to start your investment journey. We’re talking about the megatrends that drive ASX’s most innovative actions. Know everything here

Previous Immutep Leader in the development of immunotherapy for cancer and autoimmune diseases - ShareCafe
Next Hillsborough County - Hillsborough County offices, most facilities closed for Labor Day

No Comment

Leave a reply

Your email address will not be published. Required fields are marked *